EP2662373A1 — Salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Assigned to Opko Health Inc · Expires 2013-11-13 · 13y expired
What this patent protects
Disclosed is a hydrochloride crystalline salt form of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1, 7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
USPTO Abstract
Disclosed is a hydrochloride crystalline salt form of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1, 7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.